# Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

> **NCT00812266** · PHASE3 · TERMINATED · sponsor: **Danish Oncological Lung Cancer Group** · enrollment: 281 (actual)

## Conditions studied

- Extensive Disease
- First-Line
- Small Cell Lung Cancer

## Interventions

- **DRUG:** topotecan + cisplatin
- **DRUG:** Etoposide + carboplatin

## Key facts

- **NCT ID:** NCT00812266
- **Lead sponsor:** Danish Oncological Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2013-12
- **Final completion:** 2015-01
- **Target enrollment:** 281 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00812266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00812266, "Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00812266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*